Roche announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or wet age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.
- Read more about FDA approves Susvimo for macular degeneration
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/fda-approves-susvimo-for-macular-degeneration
No comments:
Post a Comment